株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の核医学向け放射性同位元素(RI)市場:種類・製品・応用分野・地域別 - 成長、動向、予測

Nuclear Medicine Radioisotopes Market - Growth, Trends, and Forecast (2019 - 2024)

発行 Mordor Intelligence LLP 商品コード 661020
出版日 ページ情報 英文 119 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=111.74円で換算しております。
Back to Top
世界の核医学向け放射性同位元素(RI)市場:種類・製品・応用分野・地域別 - 成長、動向、予測 Nuclear Medicine Radioisotopes Market - Growth, Trends, and Forecast (2019 - 2024)
出版日: 2019年03月01日 ページ情報: 英文 119 Pages
概要

世界の核医学向け放射性同位元素(RI)市場は、2017年に139億米ドルと評価され、2018年から2023年にかけては12.3%のCAGRで推移することが予測されています。2017年には全体の約40%のシェアを握る北米が最大市場となりましたが、予測期間においてはアジア太平洋市場が最大の成長率を示す見通しです。

当レポートでは、世界の核医学向け放射性同位元素(RI)市場を調査し、種類・応用分野・地域別の市場規模の推移と予測、市場動向、成長要因・阻害要因ならびに市場機会・課題の分析、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 イントロダクション

  • 市場の定義

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 主な影響要因

第5章 市場の概要

  • 現在の市場シナリオ
  • ファイブフォース分析
    • 買い手の交渉力
    • 供給企業の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係

第6章 成長要因、阻害要因、市場機会、課題

  • 市場の成長要因
    • 癌および心臓病の発症率の上昇
    • 核医学の応用拡大
    • SPECTおよびPETの用途拡大
    • 健康に対する患者の意識向上
  • 市場の阻害要因
    • 償還制度の複雑性
    • 規制上の課題
  • 市場機会
  • 主な課題

第7章 市場セグメンテーション

  • 種類別
    • テクネチウム-99m(Tc-99m)
    • タリウム-201(Tl-201)
    • ヨウ素(I-123)
    • ガリウム-67(Ga-67)
    • フッ素-18
    • ルビジウム-82(Rb-82)
    • その他
  • 応用分野別
    • 腫瘍
    • 心臓病
    • リンパ腫
    • 甲状腺
    • 神経
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • その他の地域

第8章 競合情勢

  • 合併および買収分析
  • 合意、コラボレーション、パートナーシップ
  • 新製品の発売

第9章 主要企業

  • Agfa-Gevaert Group
  • Braco
  • Cardiarc Ltd
  • Cardinal Health Inc.
  • CMR Naviscan (Gamma Medica Inc.)
  • Curium
  • Digirad Corporation
  • GE Healthcare
  • Nordion (Canada) Inc.
  • NTP Radioisotopes SOC Ltd
  • Positron Corp.
  • Segami Corporation
  • Siemens Healthcare

第10章 市場の将来展望

目次
Product Code: 54625

Market Overview

Increasing cases of cancer and cardiac ailments are the major drivers for the nuclear medicines radioisotopes market. Nuclear medicine has a huge potential in treating cancer and cardiac diseases. Growth of medical imaging is an opportunity for the growth of the global nuclear medicine radioisotope market, as both markets are correlated. Radiopharmaceuticals are approved by the Food and Drug Administration (FDA) as either drugs or biologics. They meet the statutory definition of drugs under Section 1861(t) of the Social Security Act because they either are included in the various drug compendia or recognized by hospital medical staff as drugs. Historically, nuclear medicine has been well established as a therapeutic modality for thyroid cancer, Graves' disease, hyperthyroidism, and bone pain palliation, associated with skeletal metastasis. Hence, the broadening applications of radioisotopes are expected to propel market growth.

Scope of the Report

As per the scope of the report, medical radioisotopes are defined as safe radioactive substances that are primarily used in the diagnosis of medical conditions. These radioisotopes, used in a diagnosis, emit gamma rays of energy that are sufficient to escape from the body. The rays also have a short half-life, which is apt, since the rays can decay as soon as the imaging is completed.

Key Market Trends

Oncology Segment is Expected to Exhibit Fastest Growth Rate Over the Forecast Period

Radiotherapy can be used to treat various medical conditions, especially cancer, using radiation to weaken or destroy particular targeted cells. PET, which is a precise technique, uses isotopes produced in a cyclotron. It is highly used for a clinical role in oncology, with fluorine-18 as the tracer, and is proven to be the most accurate non-invasive method of detecting and evaluating most cancers. A new field for cancer treatment is targeted alpha therapy (TAT) or alpha radio-immunotherapy, especially for the control of dispersed cancers. Nuclear medicine is proven effective in oncology in several roles, spanning the course of the disease, including the characterization of a mass, staging, restaging, and monitoring of therapeutic response. Hence, owing to these associated factors, the oncology segment is expected to exhibit the fastest growth rate.

North America captured the Largest Market Share and is Expected to Retain its Dominance

North America captured the largest market share in the nuclear medicine radioisotopes market. The United States was the largest contributor to the revenue of North America, and is expected to retain its dominance owing to the higher procedural volume and increasing adoption of the nuclear medicine isotopes for various therapeutic applications. Bone scintigraphy is the next most common nuclear medicine procedure performed in the United States, but it represents only 17% of procedures. The volume of PET procedures in the United States is approximately 1.5 million per year. Oncology accounts for more than 90% of the PET and PET/CT procedures performed, whereas cardiology and neurology account for about 4% each. Canada is the largest producer of Technetium-99m. Due to the use of Tc-99m in radiopharmaceuticals, the market is expected to grow at a tremendous rate in Canada. 80% of the nuclear medicine market is driven by Tc-99m in various diagnostic procedures and treatments. Considering these factors associated with the United States and Canada, the North American market is expected to experience accelerated growth rates and market dominance.

Competitive Landscape

There is high competition among the players of the global nuclear medicine radioisotopes market. However, this competition is not by virtue of competitive pricing or product differentiation. Additionally, big players of the pharmaceutical and biotechnology industries are leveraging their huge capital reserves to venture into this market, which is further increasing the competition. GE Healthcare,NTP Radioisotopes SOC Ltd, Nordion (Canada) Inc., Siemens Healthcare, and Positron Corp. are some of the major players in the nuclear medicine radioisotopes market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Incidences of Cancer and Cardiac Disorders
    • 4.2.2 Widening Applications of Nuclear Medicine
    • 4.2.3 Increasing SPECT and PET Applications
    • 4.2.4 Increasing Patient Awareness for Healthcare
  • 4.3 Market Restraints
    • 4.3.1 Reimbursement Complications
    • 4.3.2 Regulatory Issues
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Type of Radioisotopes
    • 5.1.1 Technetium-99m (Tc-99m)
    • 5.1.2 Thallium-201 (Tl-201)
    • 5.1.3 Iodine (I-123)
    • 5.1.4 Fluorine-18
    • 5.1.5 Rubidium-82 (Rb-82)
    • 5.1.6 Iodine-131 (I-131)
    • 5.1.7 Lutetium-177 (Lu-177)
    • 5.1.8 Radium-223 (Ra-223) & Alpharadin
    • 5.1.9 Actinium-225 (Ac-225)
    • 5.1.10 Others
  • 5.2 Application
    • 5.2.1 Oncology
    • 5.2.2 Cardiology
    • 5.2.3 Lymphoma
    • 5.2.4 Thyroid
    • 5.2.5 Neurology
    • 5.2.6 Other Applications
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Rest of the World

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Agfa-Gevaert Group
    • 6.1.2 Cardiarc Ltd
    • 6.1.3 Digirad Corporation
    • 6.1.4 CMR Naviscan (Gamma Medica Inc.)
    • 6.1.5 GE Healthcare
    • 6.1.6 Positron Corp.
    • 6.1.7 Segami Corporation
    • 6.1.8 Siemens Healthcare GmBH
    • 6.1.9 Nordion (Canada) Inc.
    • 6.1.10 NTP Radioisotopes SOC Ltd
    • 6.1.11 Bracco S.p.A
    • 6.1.12 Cardinal Health Inc.
    • 6.1.13 Curium

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top